Precigen Indemnitees definition

Precigen Indemnitees has the meaning set forth in Section 9.2.

Precigen Indemnitees has the meaning set forth in Section 8.2. 1.67 “Product Infringement” has the meaning set forth in Section 6.3(b). 1.68 “Program” means, as applicable, the TCR Program and the NK Cells and Gamma Delta T Cell Program. 1.69 “Regulatory Approval” means all approvals that are necessary for the commercial sale of product in the applicable field in a given country or regulatory jurisdiction. 1.70 “Regulatory Authority” means, in a particular country or jurisdiction, any applicable Governmental Authority involved in granting Regulatory Approval in such country or jurisdiction. 1.71 “Regulatory Materials” means regulatory applications, submissions, notifications, communications, correspondence, registrations, Regulatory Approvals and/or other filings made to, received from or otherwise conducted with a Regulatory Authority in order to Develop, manufacture, market, sell or otherwise Commercialize a Licensed Product in a particular country or jurisdiction. 1.72 “Releasees” has the meaning set forth in Section 3.4(a). 1.73 “Released Claims” has the meaning set forth in Section 3.4(a). 1.74 “Research” means non-clinical studies of a product conducted before the filing of an IND for such product. 1.75 “Sleeping Beauty Intellectual Property” means patent families [*****] and [*****] as detailed in Exhibit A. 1.76 “Sublicensee” means any Third Party granted a sublicense, covenant not to sue, forbearance agreement, co-promotion agreement or other similar arrangement (a “Sublicense”) by Alaunos to the rights licensed to Alaunos under Section 2.1(a) or Section 2.1(b). 1.77 “T-Cell” means a T-lymphocyte, including alpha beta T cells and gamma delta T cells. 1.78 “TCR” means T-cell receptor complex. 1.79 “TCR Exclusive Product” means any biological product, process or therapy that includes a TCR for a Neo-antigen, including all forms, formulations, presentations, doses, administrations and package configurations. 1.80 “TCR Exclusive Program” means a program(s) of Research and Development focused on Developing TCRs designed for Neo-antigens.

Examples of Precigen Indemnitees in a sentence

• The foregoing indemnity obligation shall not apply to the extent that (i) the Precigen Indemnitees fail to comply with the indemnification procedures set forth in Section 9.3 and Ziopharm’s defense of the relevant Claims is prejudiced by such failure, or (ii) any Claim arises from or is based on any activity set forth in Section 9.1(c) or 9.1(d) for which Precigen is obligated to indemnify the Ziopharm Indemnitees under Section 9.1.

• The foregoing indemnity obligation shall not apply to the extent that (i) the Precigen Indemnitees fail to comply with the indemnification procedures set forth in Section 8.3 and Alaunos’ defense of the relevant Claims is prejudiced by such failure, or (ii) any Claim arises from or is based on any activity set forth in Section 8.1(c) or 8.1(d) for which Precigen is obligated to indemnify the Alaunos Indemnitees under Section 8.1.

• The foregoing indemnity obligation shall not apply to the extent that (i) the Precigen Indemnitees fail to comply with the indemnification procedures set forth in Section 9.3 and Ziopharm’s defense of the relevant Claims is prejudiced by such failure, or (ii) any Claim arises from or is based on any activity set forth in Section 9.1(c) or 9.1(d) for which Precigen is obligated to indemnify the Ziopharm Indemnitees under Section 9.1. 9.

• The foregoing indemnity obligation shall not apply to the extent that (i) the Ziopharm Indemnitees fail to comply with the indemnification procedures set forth in Section 9.3 and Precigen’s defense of the relevant Claims is prejudiced by such failure, or (ii) any Claim arises from or is based on any activity set forth in Section 9.2(c) or 9.2(d) for which Ziopharm is obligated to indemnify the Precigen Indemnitees under Section 9.2. 9.

• The Company is domiciled in the Cayman Islands and invests predominantly in Vietnamese companies, which are mostly listed companies.

• The foregoing indemnity obligation shall not apply to the extent that (i) the Alaunos Indemnitees fail to comply with the indemnification procedures set forth in Section 8.3 and Precigen’s defense of the relevant Claims is prejudiced by such failure, or (ii) any Claim arises from or is based on any activity set forth in Section 8.2(b) or 8.2(c) for which Alaunos is obligated to indemnify the Precigen Indemnitees under Section 8.2.